Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | NOVARTIND Novartis India Limited Pharma · Small | GUFICBIO Gufic Biosciences Limited Pharma · Small | ZOTA Zota Health Care LImited Pharma · Small | DCAL Dishman Carbogen Amcis Limited Pharma · Small |
|---|---|---|---|---|
| Final Score | 45 | 27 | 28 | 55 |
| Verdict | WATCHLIST | OVERVALUED | OVERVALUED | FAIR VALUE |
| Style | Financial Turnaround | OVERVALUED | OVERVALUED | Growth at Value |
| Piotroski | 7/9 | 8/9 | 5/9 | 8/9 |
| Valuation | 5/30 | 0/30 | 1/30 | 16/30 |
| Growth | 15/25 | 12/25 | 14/25 | 20/25 |
| Quality | 2/20 | 0/20 | 0/20 | 0/20 |
| Balance Sheet | 13/15 | 8/15 | 7/15 | 4/15 |
| Cash Flow | 5/10 | 2/10 | 3/10 | 10/10 |
| Price | ₹1,331.4 | ₹384.5 | ₹1,211.2 | ₹189 |
| P/E | 36.90 | 60.50 | 147.00 | 29.80 |
| P/B | 4.20 | 5.84 | 4.73 | 0.44 |
| ROE | 11.60% | 10.10% | 4.74% | 1.58% |
| ROCE | 16.20% | 12.30% | 6.68% | 3.15% |
| Debt / Equity | 0.00 | 0.61 | 0.02 | 0.46 |
| FCF Yield | 1.89% | 0.36% | — | 8.34% |
| Dividend Y | 1.80% | 0.03% | 0.08% | — |
| Altman Z | 8.13 | 5.38 | 8.00 | 1.72 |
| Promoter % | 70.68% | 72.50% | 49.38% | 59.32% |
| Mkt Cap (₹Cr) | 3435.00 | 3883.00 | 4195.00 | 2951.00 |
| Graham # | ₹530.16 | ₹97.71 | ₹215.47 | ₹244.17 |
| Fair PE | 42.0 | 42.0 | 42.0 | 42.0 |
| MoS % | +16.0% | -43.0% | -257.8% | +27.6% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startNOVARTIND138
GUFICBIO80
ZOTA205
DCAL99